<DOC>
	<DOCNO>NCT02642159</DOCNO>
	<brief_summary>Primary Objective : To demonstrate superiority alirocumab comparison usual care reduction non-high-density lipoprotein cholesterol ( non-HDL-C ) patient type 2 diabetes mixed dyslipidemia high cardiovascular risk non-HDL-C adequately control maximally tolerate statin therapy . Secondary Objectives : - To demonstrate whether alirocumab superior comparison usual care effect lipid parameter ( ie , low-density lipoprotein cholesterol ( LDL-C ) , apolipoprotein B ( Apo B ) , total cholesterol ( Total -C ) , lipoprotein ( Lp [ ] ) , high-density lipoprotein cholesterol ( HDL-C ) , triglyceride ( TGs ) , triglyceride rich lipoprotein ( TGRLs ) , apolipoprotein A-1 ( Apo A-1 ) , apolipoprotein C-III ( Apo C-III ) , lipid subfractions nuclear magnetic resonance ( NMR ) spectroscopy ( ie , LDL-C particle size LDL , low-density lipoprotein [ VLDL ] , HDL , intermediate-density lipoprotein [ IDL ] particle number ) . - To assess change diabetes parameter alirocumab vs. usual care treatment . - To demonstrate safety tolerability alirocumab . - To evaluate treatment acceptance alirocumab . - To evaluate PCSK9 concentration antibody development . - To demonstrate superiority alirocumab vs. fenofibrate non-HDL-C lipid parameter ( subgroup analysis ) .</brief_summary>
	<brief_title>Efficacy Safety Alirocumab Versus Usual Care Top Maximally Tolerated Statin Therapy Patients With Type 2 Diabetes Mixed Dyslipidemia ( ODYSSEY DM-Dyslipidemia )</brief_title>
	<detailed_description>The maximum study duration approximately 9 month per patient , include 6 month treatment period , screen period 3 week , 8 week safety observation period . If need purpose scientific communication , first-step analysis ( efficacy safety ) perform Week 24 cut-off date . A second-step analysis perform patient complete study include final update safety analysis .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Inclusion criterion : Patients type 2 diabetes mixed dyslipidemia whose nonhighdensity lipoprotein cholesterol ( nonHDLC ) adequately control stable , maximum dose/regimen statin tolerate patient . 18 year age . Documented history atherosclerotic cardiovascular disease ( ASCVD ) least one additional cardiovascular risk factor . NonHDLC 100 mg/dL great . Triglycerides great equal 150 mg/dL less 500 mg/dL . Stable antihyperglycemic agent least 3 month . No change weight 5 kg within prior 3 month . On stable dose medication know influence weight and/or lipid within last 3 month . Exclusion criterion : Use lipid modify therapy statins within last 4 week ( eg , ezetimibe , fenofibrate , nicotinic acid , omega3 fatty acid , etc . ) use counter products/nutraceuticals know impact lipid ( eg , red yeast rice ) within last 4 week . Currently drink 2 standard alcoholic drink per day . Body Mass Index ( BMI ) &gt; 45 kg/mÂ² currently enrol weight loss program still active phase weight loss . Glycosylated hemoglobin ( HbA1c ) 9 % great . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>